BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

被引：15

作者：

Avivi, Irit ^{[1
,2
]}

Luttwak, Efrat ^{[1
,2
]}

Saiag, Esther ^{[3
]}

Halperin, Tami ^{[4
]}

Haberman, Shira ^{[1
]}

Sarig, Ariel ^{[1
]}

Levi, Sivan ^{[1
]}

Aharon, Anat ^{[1
,2
]}

Herishanu, Yair ^{[1
,2
]}

Perry, Chava ^{[1
,2
]}

机构：

[1] Tel Aviv Sourasky Med Ctr, Dept Hematol, 6 Weizmann St, IL-64239 Tel Aviv, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Tel Aviv Ichilov Sourasky Med Ctr, Med Syst Operat Unit, Tel Aviv, Israel

[4] Tel Aviv Sourasky Med Ctr, Dept Virol, Tel Aviv, Israel

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 196卷 / 06期

关键词：

BNT162b2; COVID-19 vaccine booster; B-cell non-Hodgkin lymphoma; humoral response; RITUXIMAB TREATMENT; RECONSTITUTION; EFFICACY; SINGLE;

D O I：

10.1111/bjh.18029

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine booster in 44 B-cell non-Hodgkin lymphoma (B-NHL) patients who failed to respond to two prior doses [42 previously exposed to anti-CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti-CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B-NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B-NHL that completed anti-CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.

引用

页码：1329 / 1333

页数：5

共 18 条

[1] B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny [J].

Anolik, Jennifer H. ;

Friedberg, Jonathan W. ;

Zheng, Bo ;

Barnard, Jennifer ;

Owen, Teresa ;

Cushing, Emily ;

Kelly, Jennifer ;

Milner, Eric C. B. ;

Fisher, Richard I. ;

Sanz, Inaki .

CLINICAL IMMUNOLOGY, 2007, 122 (02) :139-145

[2] Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in aging [J].

Avivi, Irit ;

Zisman-Rozen, Simona ;

Naor, Shulamit ;

Dai, Isabelle ;

Benhamou, David ;

Shahaf, Gitit ;

Tabibian-Keissar, Hilla ;

Rosenthal, Noemie ;

Rakovsky, Aviya ;

Hanna, Ammuri ;

Shechter, Arik ;

Peled, Eli ;

Benyamini, Noam ;

Dmitrukha, Ekaterina ;

Barshack, Iris ;

Mehr, Ramit ;

Melamed, Doron .

AGING CELL, 2019, 18 (04)

[3] Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].

Bar-On, Yinon M. ;

Goldberg, Yair ;

Mandel, Micha ;

Bodenheimer, Omri ;

Freedman, Laurence ;

Kalkstein, Nir ;

Mizrahi, Barak ;

Alroy-Preis, Sharon ;

Ash, Nachman ;

Milo, Ron ;

Huppert, Amit .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400

[4] Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial [J].

Branagan, Andrew R. ;

Duffy, Eamon ;

Albrecht, Randy A. ;

Cooper, Dennis L. ;

Seropian, Stuart ;

Parker, Terri L. ;

Gan, Geliang ;

Li, Fangyong ;

Zelterman, Daniel ;

Boddupalli, Chandra Sekhar ;

Zhang, Lin ;

Verma, Rakesh ;

Ferencz, Thomas M. ;

Dhodapkar, Madhav V. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (05) :296-+

[5] B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome [J].

Colucci, Manuela ;

Carsetti, Rita ;

Cascioli, Simona ;

Casiraghi, Federica ;

Perna, Annalisa ;

Rava, Lucille ;

Ruggiero, Barbara ;

Emma, Francesco ;

Vivarelli, Marina .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (06) :1811-1822

[6] SARS-CoV-2 Variants in Patients with Immunosuppression [J].

Corey, Lawrence ;

Beyrer, Chris ;

Cohen, Myron S. ;

Michael, Nelson L. ;

Bedford, Trevor ;

Rolland, Morgane .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (06) :562-566

[7] Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays [J].

DomBourian, Melkon G. ;

Annen, Kyle ;

Huey, Leah ;

Andersen, Gillian ;

Merkel, Patricia A. ;

Jung, Sarah ;

Dominguez, Samuel R. ;

Knight, Vijaya .

JOURNAL OF IMMUNOLOGICAL METHODS, 2020, 486

[8] Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies [J].

Gurion, Ronit ;

Rozovski, Uri ;

Itchaki, Gilad ;

Gafter-Gvili, Anat ;

Leibovitch, Chiya ;

Raanani, Pia ;

Ben-Zvi, Haim ;

Szwarcwort, Moran ;

Taylor-Abigadol, Mor ;

Dann, Eldad J. ;

Horesh, Nurit ;

Inbar, Tsofia ;

Tzoran, Inna ;

Lavi, Noa ;

Fineman, Riva ;

Ringelstein-Harlev, Shimrit ;

Horowitz, Netanel A. .

HAEMATOLOGICA, 2022, 107 (03) :715-720

[9] Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma [J].

Hahn, Michael ;

Schnitzler, Paul ;

Schweiger, Brunhilde ;

Kunz, Christina ;

Ho, Anthony D. ;

Goldschmidt, Hartmut ;

Schmitt, Michael .

HAEMATOLOGICA, 2015, 100 (07) :E285-E288

[10] COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study [J].

Ip, Andrew ;

Mato, Anthony ;

Intrator, Jordan ;

Howard, Nicholas P. ;

Petrillo, Alessandra ;

Vicioso, Rosalba ;

Sebti, Rani ;

Cicogna, Cristina ;

Magarelli, Gabriella ;

Leslie, Lori A. ;

Goy, Andre H. ;

Feldman, Tatyana A. .

BLOOD, 2020, 136

← 1 2 →